Status:
COMPLETED
Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients
Lead Sponsor:
University Hospital, Akershus
Conditions:
Pain Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The investigators aim to establish whether the intravenous or the subcutaneous route of administration has clinically significant advantages when parenteral administration of morphine is started with ...
Detailed Description
Intravenous administration has theoretical advantages in more predictable pharmacokinetics and shorter time to maximum effect. Subcutaneous administration is less invasive, requires less specialized p...
Eligibility Criteria
Inclusion
- Unsatisfactory pain control despite titration of oral or transdermal opioids
- Planned discharge to home or nursing home
Exclusion
- Estimated survival time \<2 weeks
- A clear indication for either intravenous or subcutaneous administration
- Patient unable to report patient reported outcomes needed in the study due to language barriers or cognitive impairment
- Impossible to establish venous access
Key Trial Info
Start Date :
March 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05236647
Start Date
March 8 2022
End Date
January 31 2025
Last Update
March 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus University Hospital
Lørenskog, Norway, 1478